Dose escalation of second-line sunitinib results in rapid partial remission of multiple hepatic metastases.
Standard
Dose escalation of second-line sunitinib results in rapid partial remission of multiple hepatic metastases. / Guevremont, Catherine; Mija, Florin I; Isbarn, Hendrik; Jeldres, Claudio; Lughezzani, Giovanni; Sun, Maxine; Audet, Pascale; Perrotte, Paul; Karakiewicz, Pierre I.
in: CUAJ-CAN UROL ASSOC, Jahrgang 3, Nr. 6, 6, 2009, S. 92-93.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Dose escalation of second-line sunitinib results in rapid partial remission of multiple hepatic metastases.
AU - Guevremont, Catherine
AU - Mija, Florin I
AU - Isbarn, Hendrik
AU - Jeldres, Claudio
AU - Lughezzani, Giovanni
AU - Sun, Maxine
AU - Audet, Pascale
AU - Perrotte, Paul
AU - Karakiewicz, Pierre I
PY - 2009
Y1 - 2009
N2 - A 58-year-old man with metastatic clear cell renal cell carcinoma on sunitinib therapy, who previously failed on sorafenib, was found to have progression of multiple hepatic metastases; he was on a standard sunitinib dose of 50 mg/day (4 weeks on, 2 weeks off). Due to the unavailability of alternative therapies, a sunitinib dose escalation of 50 mg/day was attempted. After one 6-week cycle of continuously dosed sunitinib 50 mg, the hepatic lesions regressed. After the second cycle, virtual disappearance of the lesions was recorded. There was no added toxicity. These findings suggest that sunitinib dose escalation to 50 mg/day using continuous daily administration dosing might represent a valid, effective and well-tolerated therapeutic option in patients who progress on standard sunitinib therapy.
AB - A 58-year-old man with metastatic clear cell renal cell carcinoma on sunitinib therapy, who previously failed on sorafenib, was found to have progression of multiple hepatic metastases; he was on a standard sunitinib dose of 50 mg/day (4 weeks on, 2 weeks off). Due to the unavailability of alternative therapies, a sunitinib dose escalation of 50 mg/day was attempted. After one 6-week cycle of continuously dosed sunitinib 50 mg, the hepatic lesions regressed. After the second cycle, virtual disappearance of the lesions was recorded. There was no added toxicity. These findings suggest that sunitinib dose escalation to 50 mg/day using continuous daily administration dosing might represent a valid, effective and well-tolerated therapeutic option in patients who progress on standard sunitinib therapy.
M3 - SCORING: Zeitschriftenaufsatz
VL - 3
SP - 92
EP - 93
JO - CUAJ-CAN UROL ASSOC
JF - CUAJ-CAN UROL ASSOC
SN - 1911-6470
IS - 6
M1 - 6
ER -
